Valuation: Definium Therapeutics, Inc.

Market Cap 4.31B 3.83B 3.55B 3.23B 6.1B 409B 6.2B 42.72B 16.75B 214B 16.19B 15.84B 681B P/E 2026 *
-10.1x
P/E 2027 * -15.9x
Enterprise Value 3.28B 2.92B 2.7B 2.46B 4.64B 312B 4.72B 32.51B 12.75B 163B 12.32B 12.06B 518B EV / Sales 2026 *
-
EV / Sales 2027 * 119x
Free-Float
97.43%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Definium Therapeutics, Inc.

1 day-6.30%
1 week-13.01%
Current month-15.66%
1 month-17.01%
3 months-27.52%
6 months+41.53%
Current year+139.73%
1 week 32.02
Extreme 32.0175
36.3
1 month 32.02
Extreme 32.0175
40.39
Current year 12.88
Extreme 12.882
49.7
1 year 10.46
Extreme 10.4646
49.7
3 years 2.41
Extreme 2.41
49.7
5 years 2.12
Extreme 2.12
49.7
10 years 1.25
Extreme 1.249499
86.55
Manager TitleAgeSince
Chief Executive Officer 37 2021-06-08
Director of Finance/CFO 52 2025-06-01
Chief Tech/Sci/R&D Officer 46 2021-01-31
Director TitleAgeSince
Director/Board Member 37 2021-12-12
Director/Board Member 67 2021-09-28
Chairman 69 2021-12-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26 Sell

General Counsel

-14,051 0.0106%
9/25/26 Sell

Chief Technology Officer

-10,853 0.0082%
9/25/26 Sell

Executive/Senior Manager

-3,097 0.0023%
Change 5-day change 1-year change 3-year change Capi.($)
-6.30%-13.01%+135.16%+991.84% 4.31B
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -2.12%-1.62%+54.48%+184.07% 37.67B
Weighted average by Cap. -2.24%-0.64%+45.29%+106.79%

Financials

2026 *2027 *
Net sales - 29.32M 26.07M 24.16M 21.98M 41.48M 2.78B 42.15M 290M 114M 1.45B 110M 108M 4.63B
Net income -376M -334M -310M -282M -532M -35.67B -540M -3.72B -1.46B -18.62B -1.41B -1.38B -59.35B -273M -243M -225M -205M -387M -25.94B -393M -2.71B -1.06B -13.54B -1.03B -1B -43.15B
Net Debt -1.03B -916M -849M -773M -1.46B -97.83B -1.48B -10.21B -4B -51.05B -3.87B -3.79B -163B -832M -739M -685M -623M -1.18B -78.94B -1.2B -8.24B -3.23B -41.19B -3.12B -3.06B -131B
Projected Income Statement - Annual - Definium Therapeutics, Inc.
Logo Definium Therapeutics, Inc.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Employees
-
Date Price Change Volume
26-10-16 US$32.10 -6.30% 1,935,259
26-10-15 US$34.26 +0.06% 1,747,569
26-10-14 US$34.24 -0.41% 1,762,182
26-10-13 US$34.38 -2.33% 2,000,416
26-10-12 US$35.20 -4.61% 1,909,077
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Definium Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
32.10USD
Average target price
72.33USD
Spread / Average Target
+125.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Definium Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DFTX Stock